title: Pulmonary hypertension associated with lung diseases and hypoxemia.
abstract: Pulmonary hypertension that develops in the setting of underlying lung diseases such as COPD or idiopathic pulmonary fibrosis (IPF) is associated with decreased functional status, worsening hypoxemia and quality of life, and increased mortality. This complication of lung disease is complex in its origin and carries a unique set of diagnostic and therapeutic issues. This review attempts to provide an overview of mechanisms associated with the onset of pulmonary hypertension in COPD and IPF, touches on appropriate evaluation, and reviews the state of knowledge on treating pulmonary hypertension related to underlying lung disease.
authors.affiliation: Northwestern Pulmonary Hypertension Program, 676 St Claire Suite 1400, Chicago, IL, 60611, USA. m-cuttica@northwestern.edu.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Cuttica
mesh_terms: D065128:Endothelin Receptor Antagonists / Q000627:therapeutic use; D011464:Epoprostenol / Q000627:therapeutic use; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D000860:Hypoxia / Q000150:complications*; D054990:Idiopathic Pulmonary Fibrosis / Q000150:complications*; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications*; D011788:Quality of Life; D012307:Risk Factors; D020181:Sleep Apnea, Obstructive / Q000150:complications
chemical_list: D065128:Endothelin Receptor Antagonists; D058986:Phosphodiesterase 5 Inhibitors; D011464:Epoprostenol
keywords: COPD; Idiopathic pulmonary fibrosis; Pulmonary hypertension; Treatment